Latest News

  • A Restless Illumina on Display in CEO's J.P. Morgan Address

    By Aaron Krol  January 13, 2015 | Yesterday, Illumina CEO Jay Flatley gave his annual address at the J.P. Morgan Healthcare Conference in San Francisco, one year after using his J.P. Morgan slot to announce the launch of the HiSeq X, the fastest

    May 27, 2015
  • SV Bio Relaunched as Lifecode, Maker of LDTs

    By Bio IT World Staff  January 20, 2015 | SV Bio today announced a new name, a new focus, and a new product a next generation sequencing (NGS) based oncology assay, the Pan Cancer Somatic Panel (PCSP). Silicon Valley Biosystems was

    May 27, 2015
  • QIAGEN Gets European Approval for Lung Cancer Liquid Biopsy

    By Clinical Informatics News Staff January 21, 2015 | QIAGEN’s circulating tumor DNA companion diagnostic for lung cancer has been granted CE IVD marking in 30 European countries, the company announced. The diagnostic is designed as a companion for Astra Zeneca’s

    May 27, 2015
  • Claritas Announces $15m Funding Round

    By Bio IT World Staff January 26, 2015 | Claritas Genomics announced today that it has secured $15 million in capital for its Series B round to expand its commercial operations, launch new next generation sequencing based tests for diagnosis of

    May 27, 2015
  • Appistry Launches CloudDx Translational from NIH Tool

    By Bio IT World Staff   January 26, 2015 | Appistry today launched Appistry CloudDx Translational, a “sister product” to the CloudDx platform launched last June, now renamed CloudDx Clinical. CloudDx Translational is a cloud based system for conducting patient centered translational research.

    May 27, 2015
  • A New Beginning for Semiconductor Sequencing

     By Aaron Krol   February 2, 2015 | In December 2010, Ion Torrent of Connecticut launched the first commercial product based on a new technology called semiconductor sequencing. The Ion PGM, sold at half the price of its nearest competitors, was taking

    May 27, 2015
  • Invitae Raises $102 Million for 'Universal' Genetic Test

    February 12, 2015 | Invitae, a genetic testing company founded by former Genomic Health CEO Randy Scott, raised $102 million today in an initial public offering. While many in the field of genomics have predicted that plummeting costs of DNA sequencing

    May 27, 2015
  • Humbled Myriad Caves on BRCA Patents

    By Aaron Krol   January 28, 2015 | The long courtroom fights are at long last coming to an end as Myriad Genetics has announced it will settle its complex web of suits and countersuits and end claims to ownership of certain

    May 27, 2015
  • BGI Releases Non-Invasive Prenatal Testing Results

    1 30 15 Additional details about the NIFTY test were added in paragraph four.    By Bio IT World StaffJanuary 29, 2015 | BGI published the results of its non invasive prenatal test, the NIFTY, this month in Ultrasound Obstetrics and Gynecology (DOI 10.1002

    May 27, 2015
  • Obama Announces $215m Precision Medicine Investment for NIH, FDA

    By Allison Proffitt   January 30, 2015 | President Obama will outline this morning his proposed investments to improve health and treat disease through precision medicine. The president will set out a $215m plan, “to build the infrastructure we need to accelerate

    May 27, 2015
  • Foundation Medicine and H3 Biomedicine Sign Oncology Agreement

    By Bio IT World Staff  February 23, 2015 | Foundation Medicine and H3 Biomedicine announced a multi year collaboration today for the discovery and development of precision medicines in oncology. The collaboration marries Foundation Medicine’s comprehensive genomic knowledgebase of more than 35,000 genomic profiles, FoundationCORE,

    May 27, 2015
  • Association for Molecular Pathology Releases Model for Pricing Genomic Tests

    By Clinical Informatics News Staff   March 5, 2015 | The Association for Molecular Pathology (AMP), the main organization representing the interests of laboratory professionals performing molecular diagnostics in the U.S., has published a series of models estimating the cost and value

    May 27, 2015
  • Merck Serono Signs Up with Illumina's Universal Oncology Test

    By Bio IT World Staff  March 10, 2015 | Illumina has brought another major pharmaceutical partner on board for its Universal Oncology Test program, an effort to build a next generation sequencing based gene panel covering all major cancer related mutations

    May 26, 2015
  • Genome in a Bottle Uncapped

    Diagnostics World Brief | Creators of DNA technologies now have an important new tool for understanding how well their instruments and tests are performing a DNA sample designated as a “reference material” by the National Institute of Standards and Technology. 

    May 27, 2015
  • 23andMe Therapeutics Won't Change Drug Discovery

    But it's a good move from a company that should know better than anyone how to turn genetic data into real value.  By Aaron Krol  March 17, 2015 | For as long as 23andMe has been in business, observers have

    May 14, 2015
  • Diagnostic-Maker Scanadu Lands $35M As FDA Submission Nears

    Xconomy | Scanadu, a Mountain View, CA based startup that's making a diagnostic device it likens to Star Trek's famous Tricorders, has received $35 million of Series B funding.

    May 27, 2015
  • IBM Sees Opportunities in Care Management with Watson Health

    Computerworld | After years of experiments using its Watson cognitive computing technology in medical settings, IBM announced this week the creation of a Watson Health business unit that will provide new capabilities in intelligent monitoring of patients' health data.

    May 27, 2015
  • GigaScience Paper Demonstrates Pathogen Detection on the MinION

    Diagnostics World Brief | A team of researchers led by Andy Kilianski of Maryland’s Edgewood Chemical Biological Center has published a paper demonstrating the use of the MinION nanopore sequencer to accurately identify strains of bacteria and viruses. 

    May 27, 2015
  • The Right Drug the First Time

    Diagnostics World Brief | Scientists in the growing field of pharmacogenetics believe that new DNA tests can protect patients from adverse drug responses and ineffective prescriptions. Yet it's been an uphill battle to convince payers, medical centers, and clinicians to embrace these tests in mainstream medicine.

    May 27, 2015